Generic Name and Formulations:
In vitro test; fetal fibronectin enzyme immunoassay.
Indications for FULLTERM:
Aid in assessing risk of preterm delivery in ≤7 or ≤14 days from the time of cervicovaginal sample collection in women with signs/symptoms of early preterm labor, intact amniotic membranes, and minimal cervical dilation (<3cm), sampled between ≥24 weeks and <35 weeks gestation. Aid in assessing risk of preterm delivery in <35 weeks during routine prenatal visit between 22 weeks and <31 weeks gestation in women with singleton gestation.
See literature. Not for women with advanced cervical dilatation, ruptured amniotic membranes, cervical cerclage, moderate or gross vaginal bleeding. Collect vaginal sample before any activities that may disrupt cervix (eg, coitus, cervical examinations, vaginal ultrasound, pap smear).
Lubricants, soaps, disinfectants may interfere with test results.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL